Salvage chemotherapy with temozolomide in primary CNS lymphomas: Preliminary results of a phase II trial

Michele Reni, Warren Mason, Francesco Zaja, James Perry, Enrico Franceschi, Daniele Bernardi, Stefania Dell'Oro, Caterina Stelitano, Marco Candela, Antonio Abbadessa, Andrea Pace, Roberto Bordonaro, Giancarlo Latte, Eugenio Villa, Andrés J M Ferreri

Research output: Contribution to journalArticle

Abstract

Temozolomide is a well-tolerated alkylating agent, that is able to permeate the blood-brain barrier (BBB), and has additive cytotoxicity when given with radiotherapy (RT). A phase II trial assessing temozolomide 150 mg/m 2/day, for 5 days every 28 days in primary central nervous system (CNS) lymphoma (PCNSL) patients with negative human immunodeficienct virus (HIV) serology, Eastern Cooperative Oncology Group (ECOG) performance status (PS)

Original languageEnglish
Pages (from-to)1682-1688
Number of pages7
JournalEuropean Journal of Cancer
Volume40
Issue number11
DOIs
Publication statusPublished - Jul 2004

    Fingerprint

Keywords

  • Phase II trial
  • Primary CNS lymphoma
  • Salvage therapy
  • Temozolomide

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Reni, M., Mason, W., Zaja, F., Perry, J., Franceschi, E., Bernardi, D., Dell'Oro, S., Stelitano, C., Candela, M., Abbadessa, A., Pace, A., Bordonaro, R., Latte, G., Villa, E., & Ferreri, A. J. M. (2004). Salvage chemotherapy with temozolomide in primary CNS lymphomas: Preliminary results of a phase II trial. European Journal of Cancer, 40(11), 1682-1688. https://doi.org/10.1016/j.ejca.2004.03.008